USPTO grants patent to AIM ImmunoTech’s Ampligen for endometriosis treatment: Ocala, Florida Monday, October 7, 2024, 15:00 Hrs [IST] AIM ImmunoTech Inc. announced that the Unit ...
Studies have found that endometriosis affects 10 to 15 percent of women of child-bearing age. And yet, despite how common this disease is - and how utterly debilitating its symptoms can be - we still ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both ...